{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:01Z","timestamp":1787664241408,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd","award":["Chugai Pharmaceutical Co., Ltd"],"award-info":[{"award-number":["Chugai Pharmaceutical Co., Ltd"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glofitamab is a T-cell engaging CD20xCD3 bispecific antibody approved for treatment of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) in the US and Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase I study (jRCT2080225077) investigated safety, pharmacokinetics, and efficacy of glofitamab in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL). Patients received obinutuzumab pretreatment (1000\u00a0mg) 7\u00a0days before first glofitamab administration. Glofitamab was given with step-up dosing on Cycle (C)1 Day (D)1 and D8, then at target dose every 3\u00a0weeks from C2D1 (7\u00a0days after C1D8) (Cohort 1: 2.5\/10\/16\u00a0mg; Cohort 2: 2.5\/10\/30\u00a0mg) until progression. Primary endpoints were safety and pharmacokinetics; secondary endpoint was efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight patients with B-NHL (DLBCL,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095; follicular lymphoma [FL],\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092; transformed FL,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) were enrolled (Cohort 1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095; Cohort 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; median age, 64.5\u00a0years; Ann Arbor Stage III\/IV,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). The two patients with FL received no glofitamab due to hematological adverse events (AEs) after obinutuzumab. Median number of glofitamab cycles was 48 (Cohort 1) and 43 (Cohort 2). Seven patients had grade 3\/4 AEs; no grade 5 AEs were reported. Two patients had serious AEs; no dose-limiting toxicities were observed. Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1\/2\/3:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093\/\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092\/\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), predominantly in C1. Serum glofitamab concentrations showed similar time profiles in both cohorts, and exposure increased in a dose-proportional manner. Overall and complete response rates were 75.0% (6\/8 patients; Cohort 1: 3\/5 patients [60.0%]; Cohort 2: 3\/3 patients [100%]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Glofitamab demonstrated a manageable safety profile with encouraging response rates in Japanese patients with relapsed\/refractory B-NHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03110-2","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:40:00Z","timestamp":1783014000000},"page":"1975-1983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-2030","authenticated-orcid":false,"given":"Yuko","family":"Shirouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"10","key":"3110_CR1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1111\/cas.15926","volume":"114","author":"Y Usui","year":"2023","unstructured":"Usui Y, Ito H, Katanoda K et al (2023) Trends in non-Hodgkin lymphoma mortality rate in Japan and the United States: a population-based study. Cancer Sci 114(10):4073\u20134080. https:\/\/doi.org\/10.1111\/cas.15926","journal-title":"Cancer Sci"},{"issue":"1","key":"3110_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW (2011) Relapsed\/refractory diffuse large B-cell lymphoma. Hematology 2011(1):498\u2013505. https:\/\/doi.org\/10.1182\/asheducation-2011.1.498","journal-title":"Hematology"},{"issue":"4","key":"3110_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"11","key":"3110_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","volume":"3","author":"N Epperla","year":"2019","unstructured":"Epperla N, Badar T, Szabo A et al (2019) Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv 3(11):1661\u20131669. https:\/\/doi.org\/10.1182\/bloodadvances.2019000102","journal-title":"Blood Adv"},{"issue":"16","key":"3110_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"issue":"3","key":"3110_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A et al (2022) Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharm Med 36(3):163\u2013171. https:\/\/doi.org\/10.1007\/s40290-022-00428-w","journal-title":"Pharm Med"},{"issue":"10","key":"3110_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","volume":"20","author":"EC Ayers","year":"2020","unstructured":"Ayers EC, Margolis D, Landsburg DJ (2020) Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk 20(10):661\u2013667. https:\/\/doi.org\/10.1016\/j.clml.2020.05.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"3110_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387(24):2220\u20132231. https:\/\/doi.org\/10.1056\/NEJMoa2206913","journal-title":"N Engl J Med"},{"issue":"18","key":"3110_CR9","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/jco.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959\u20131970. https:\/\/doi.org\/10.1200\/jco.20.03175","journal-title":"J Clin Oncol"},{"issue":"10466","key":"3110_CR10","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M et al (2024) Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet 404(10466):1940\u20131954. https:\/\/doi.org\/10.1016\/S0140-6736(24)01774-4","journal-title":"Lancet"},{"key":"3110_CR11","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.ccr-18-0455","volume":"19","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S et al (2018) CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res 19:4785\u20134797. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0455","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"3110_CR12","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2022-157554","volume":"140","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Carlo-Stella C, Morschhauser F et al (2022) Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment. Blood 140(Supplement 1):1062\u20131064. https:\/\/doi.org\/10.1182\/blood-2022-157554","journal-title":"Blood"},{"issue":"4","key":"3110_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"3110_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"4","key":"3110_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3324\/haematol.2023.283802","volume":"109","author":"YQ Song","year":"2024","unstructured":"Song YQ, Zhang HL, Huang HQ et al (2024) Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica 109(4):1269\u20131273. https:\/\/doi.org\/10.3324\/haematol.2023.283802","journal-title":"Haematologica"},{"issue":"26","key":"3110_CR16","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"3110_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10254","key":"3110_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"27","key":"3110_CR19","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/jco.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L et al (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results From the US lymphoma CAR T consortium. J Clin Oncol 38(27):3119\u20133128. https:\/\/doi.org\/10.1200\/jco.19.02104","journal-title":"J Clin Oncol"},{"issue":"10","key":"3110_CR20","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R et al (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28(10):2145\u20132154. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","journal-title":"Nat Med"},{"issue":"7","key":"3110_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"issue":"10","key":"3110_CR22","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot R, Bachy E, Cartron G et al (2023) Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med 29(10):2593\u20132601. https:\/\/doi.org\/10.1038\/s41591-023-02572-5","journal-title":"Nat Med"},{"issue":"1","key":"3110_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41408-024-01195-4","volume":"14","author":"N Epperla","year":"2024","unstructured":"Epperla N, Lucero M, Bailey T et al (2024) Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J 14(1):210. https:\/\/doi.org\/10.1038\/s41408-024-01195-4","journal-title":"Blood Cancer J"},{"issue":"7","key":"3110_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/s1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21(7):978\u2013988. https:\/\/doi.org\/10.1016\/s1470-2045(20)30225-4","journal-title":"Lancet Oncol"},{"key":"3110_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104611","volume":"207","author":"HA Farooqi","year":"2025","unstructured":"Farooqi HA, Saffi Ullah M, Raza A et al (2025) Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Crit Rev Oncol Hematol 207:104611. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104611","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"3110_CR26","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H et al (2024) Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38(12):2653\u20132662. https:\/\/doi.org\/10.1038\/s41375-024-02410-8","journal-title":"Leukemia"},{"issue":"3","key":"3110_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim WS, Kim TM, Cho SG et al (2025) Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer 6(3):528\u2013539. https:\/\/doi.org\/10.1038\/s43018-025-00921-6","journal-title":"Nat Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03110-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:40Z","timestamp":1787663320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03110-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03110-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yuko Shirouchi received honoraria from Chugai Pharmaceuticals Ltd. Yuko Mishima has no disclosures. Suguru Fukuhara received honoraria from AbbVie, AstraZeneca, BeOne Medicines, Chugai Pharmaceuticals Ltd, Genmab, Janssen, LOXO Oncology, Mitsubishi Tanabe, Nihon Shinyaku, Ono, and Takeda. Shinichi Makita received honoraria from AbbVie, AstraZeneca, Bristol Meyers Squibb, Chugai Pharmaceuticals Ltd, Genmab, and Gilead Sciences. Koji Izutsu received research funding from AstraZeneca, AbbVie, Incyte, Chugai Pharmaceuticals Ltd, Beigene, Bristol Myers Squibb, Regeneron, Genmab, Novartis, LOXO Oncology, Yakult, Daiichi Sankyo, and Otsuka. Yasuhito Terui received honoraria from Iqvia, Janssen, Nippon Shinyaku, and MR Nintei Center. Takuro Suzuki and Takeshi Miyake are employed at Chugai Pharmaceuticals Ltd and own stock from Chugai Pharmaceuticals Ltd. Atsuko Kawasaki is employed at Chugai Pharmaceuticals Ltd. Dai Maruyama received honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai Pharmaceuticals Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squib, Genmab, Novartis, and Pfizer, research funding from Ono, Janssen, Eisai, Chugai Pharmaceuticals Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis, Otsuka, Taiho, Pfizer, and Astellas, and consultancy from Janssen, AstraZeneca, Chugai Pharmaceuticals Ltd, AbbVie, Genmab, Sanofi, Briston Myers Squibb, and Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}